Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetesopen access
- Authors
- Jin, SM[Jin, Sang-Man]; Oh, BJ[Oh, Bae Jun]; Lee, S[Lee, Suel]; Choi, JM[Choi, Jung Mook]; Yang, SJ[Yang, Soo Jin]; Park, SW[Park, Sung Woo]; Kim, KW[Kim, Kwang-Won]; Kim, JH[Kim, Jae Hyeon]; Park, CY[Park, Cheol-Young]
- Issue Date
- 1-Sep-2013
- Publisher
- YONSEI UNIV COLLEGE MEDICINE
- Citation
- YONSEI MEDICAL JOURNAL, v.54, no.5, pp.1127 - 1136
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- YONSEI MEDICAL JOURNAL
- Volume
- 54
- Number
- 5
- Start Page
- 1127
- End Page
- 1136
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/59380
- DOI
- 10.3349/ymj.2013.54.5.1127
- ISSN
- 0513-5796
- Abstract
- Purpose: Although the presence of cannabinoid type 1 (CB1) receptor in islets has been reported, the major contributor to the protective effect of rimonabant on islet morphology is unknown. We determined whether the protective effect of rimonabant on pancreatic islet morphology is valid in established diabetes and also whether any effect was independent of decreased food intake. Materials and Methods: After diabetes was confirmed, Otsuka Long-Evans Tokushima Fatty rats, aged 32 weeks, were treated with rimonabant (30 mg/kg/d, rimonabant group) for 6 weeks. Metabolic profiles and islet morphology of rats treated with rimonabant were compared with those of controls without treatment (control group), a pair-fed control group, and rats treated with rosiglitazone (4 mg/kg/d, rosiglitazone group). Results: Compared to the control group, rats treated with rimonabant exhibited reduced glycated albumin levels (p<0.001), islet fibrosis (p<0.01), and improved glucose tolerance (p<0.05), with no differences from the pair-fed control group. The retroperitoneal adipose tissue mass was lower in the rimonabant group than those of the pair-fed control and rosiglitazone groups (p<0.05). Rimonabant, pair-fed control, and rosiglitazone groups showed decreased insulin resistance and increased adiponectin, with no differences between the rimonabant and pair-fed control groups. Conclusion: Rimonabant had a protective effect on islet morphology in vivo even in established diabetes. However, the protective effect was also reproduced by pair-feeding. Thus, the results of this study did not support the significance of islet CBI receptors in islet protection with rimonabant in established obesity-associated type 2 diabetes.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/59380)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.